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Abstract 
Introduction: Chronic obstructive pulmonary disease (COPD) is frequently 
associated with comorbidities occurring either independently or as 
consequences of COPD. 
Areas covered: This review examines the interactions between the 
pathophysiology of COPD and the most frequent comorbidities, and highlights 
the need for multidimensional clinical strategies to manage COPD patients with 
comorbidities. 
Expert commentary: Most COPD patients need to be approached in a complex 
and multifactorial scenario. The diagnosis of COPD is necessarily based on the 
presence of chronic respiratory symptoms and poorly reversible airflow 
obstruction, but exacerbations and comorbidities need to be considered in the 
evaluation of disease severity and prognosis in individual patients. More 
importantly, defining the precise relationship between COPD and comorbidities 
for each patient is the basis for a correct therapeutic approach. 
Keywords: COPD, ageing, cardiovascular diseases, comorbidity, risk factors, 
smoking. 
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1.0 Introduction 
Ever since the pioneering study by Burrows et al. [1], chronic obstructive pulmonary 
disease (COPD) has been considered as a condition characterized by airflow obstruction due 
to airway and parenchymal abnormalities [2]. During the first decade of the current century, 
despite the fact that the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
committee had given more emphasis to putative inflammatory mechanisms, the role of the 
different structural changes in the airways and pulmonary parenchyma in the pathogenesis of 
airflow obstruction was overshadowed [3]. Thus, several changes have been proposed in the 
definition of COPD, the most striking of which was in 2007, when airflow obstruction was 
considered as the pulmonary component of a systemic inflammatory multi-morbid disorder 
[4]. Notwithstanding, the demonstration of airflow obstruction by spirometry was reasonably 
retained to confirm a clinical diagnosis of COPD. Finally, the GOLD committee in 2017 
went back to the definition of COPD as a “disease that is characterized by persistent 
respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities”, 
where comorbidities are considered as frequently associated conditions [5].    
COPD is characterized by a slowly progressive deterioration in lung function, mostly 
becoming evident with aging. Therefore, it is not surprising that COPD is frequently 
associated with other age-related morbid conditions, which may exist independently, or as 
consequences of COPD, or because they share common risk factors.   
The aims of this review are to examine the interactions between the pathophysiology 
of COPD and the most frequent comorbidities, and to highlight the need for multidimensional 
clinical strategies to manage COPD patients with comorbidities by suitable diagnostic 
procedures and individualized therapeutic interventions. 
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2.0 Pathophysiology of COPD and related comorbidities 
Tobacco smoking and environmental exposures are the main risk factors for COPD. 
The exposure to tobacco smoking, ever since antenatal period and early childhood, and the 
presence of other childhood risk factors, such as maternal and paternal asthma, childhood 
asthma, and respiratory infections, accelerate the rate of lung function decline and COPD [6]. 
Cohort studies indicated that subjects with COPD in the sixth decade already had the worst 
spirometry at age 10 years, when spirometry was performed from the preschool years to late 
middle age [6]. Therefore, COPD seems to have its roots in early life; then, the individual 
susceptibility associated with genetic predisposition, abnormal lung development, and 
accelerated ageing may contribute to COPD development. Putative genetic risk factors for 
COPD include the alpha-1 antitrypsin deficiency, alterations in matrix metalloproteinases 12 
(MMP12), alpha nicotinic acetylcholine receptor, and hedgehog interacting protein genes 
[7,8]. Ageing is also considered as a risk factor but its contribution in the COPD pathogenesis 
is not completely understood [5].  
 The pathology of COPD includes alterations of airways, lung parenchyma, and 
pulmonary vasculature. An increased numbers of specific inflammatory cell types (CD8+ 
Tc1 lymphocytes, neutrophils, and macrophages) in the lung due to noxious exposures may 
contribute to chronic inflammation, while structural changes (remodeling) result from 
repeated injury and repair [9]. These changes, which are considered the perpetrators of loss of 
lung function, do not always occur together, but evolve at different rates over time [5]. 
Oxidative stress, protease-anti-protease imbalance, chemotactic factors, cytokines, and 
growth factors promote and sustain inflammation, which leads to direct damage of airways 
(chronic bronchitis) and lung parenchyma (emphysema), and hence to systemic consequences 
[10-12]. Systemic inflammation contributes to skeletal muscle wasting and cachexia, and 
initiates or worsens comorbidities [5].  
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Recently it has been shown that COPD-associated airflow obstruction or emphysema 
reduce the left ventricular function and affect cardiac stroke volume [13]. Airflow limitation 
contributes to the positive intrathoracic pressure during expiration, while the loss of alveolar 
septa reduces pulmonary vascular volume [13]. Therefore, altered heart-to-lung mechanical 
interactions may affect the cardiac function, for instance determining right heart dysfunction 
secondary to pulmonary hypertension in hypoxemic patients. 
3.0 The pulmonary profile 
Although it has been recognized that COPD is a heterogeneous condition with respect 
to the underlying pulmonary pathology, current documents [5] and most guidelines [14-16] 
recommend the use of simple spirometry to diagnose COPD and grade its severity. This 
simplistic approach may lead to misclassification of several COPD subjects for a series of 
reasons.   
In early phases, abnormalities are limited to peripheral airways and need to be 
considerable to affect overall lung function tests, such as spirometry [17]. Moreover, the 
forced expiratory flow is an integrated measure of maximal expiratory flows of individual 
airways, which are determined by their caliber, stiffness, and elastic recoil pressure. Simple 
spirometry is not sensitive to evaluate regional inhomogeneity and does not allow 
distinguishing between airway and parenchymal components of airflow obstruction. For 
instance, increased total lung capacity and reduced single-breath diffusion capacity for 
carbon monoxide are sensitive to recognizing emphysema [18], but these tests are not 
considered as necessary in the routine COPD management [5].    
Furthermore, the fixed ratio FEV1/FVC<0.7 is a commonly used criterion in clinical 
practice to define airflow obstruction as per the first GOLD recommendation [3] and to 
diagnose COPD [19-21]. However, it presents some age and sex biases, which may lead to 
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over-diagnosis in older subjects and males and under-diagnosis in younger subjects and 
females.  
In the evaluation of predicted FEV1, some confounding factors related to lung 
pathology or comorbidities should be kept into account: despite similar symptoms, FEV1 
may be significantly lower in patients with dominant emphysema than in those with chronic 
bronchiolitis, due to thoracic gas compression [22]. In obesity, the ratio FEV1/FVC tends to 
increase with the body mass index (BMI), whereas FVC and FEV1 are reduced [23]. Thus, in 
obese COPD subjects the presence of airflow obstruction may go undetected, but its severity 
may be overestimated, if based on FEV1 [24,25]. 
The reduction of FEV1 is not the unique relevant abnormality of lung function in 
COPD. Considering the simple relationship FEV1 = FVC x FEV1/FVC, FEV1 reduction is 
not only due to airway narrowing or low elastic recoil pressure (low FEV1/FVC), but also to 
air trapping (low FVC). Since more than 50 years, it was known that air trapping is present in 
smokers before FEV1 or FEV1/FVC decrease [26,27]. Therefore, based on simple 
spirometry, some COPD subjects may be paradoxically classified as restricted [28]. In these 
cases, an additional investigation of absolute lung volumes may be useful for a correct 
functional classification [29].  
Furthermore, spirometry is a diagnostic test based on a forced expiratory maneuver, 
that is not commonly experienced in the daily life: the spirometric measurements are good 
survival predictors [30], but loosely correlated with patient-centered outcomes, such as 
dyspnea, quality of life, exercise tolerance [31], that are more closely related to lung 
hyperinflation than FEV1 [32].  
Imaging techniques may provide quantitative information on the extent of 
emphysema and airway wall abnormalities [33]. However, recent data have indicated that 
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combining clinical and functional data allows distinguishing patients with prevalent 
emphysema or prevalent chronic bronchitis, with an accuracy like that of high-resolution 
computerized tomography [34].  
4.0 The Co-morbidome 
Comorbidities frequently occur in patients with COPD, and the frequency of 
comorbidities is independent of the degree of airflow limitation [35]. Comorbidities 
contribute to adverse clinical outcomes in these patients and affect symptom burden, 
functional performance, hospitalization risk, and mortality. In randomized controlled trials, 
comorbidities are the primary causes of death in more than 60% of non-survivors [36,37].  
Several algorithms have been proposed to predict the relationship between 
comorbidities and COPD clinical outcomes. The COPD specific CO-morbidity Test (COTE) 
is a point scale index, based on prevalence (more than 10%) of individual comorbidities 
(congestive heart failure, coronary artery disease, atrial fibrillation, pulmonary fibrosis, lung 
cancer, anxiety, breast cancer, pancreatic cancer, esophageal cancer, diabetes/ neuropathy, 
gastric duodenal ulcer, liver cirrhosis) and their association with mortality risk overtime [38]. 
Vanfleteren et al. [39] profiled five comorbidity-based clusters: less morbidity cluster (cluster 
1), cardiovascular cluster (cluster 2), cachectic cluster (cluster 3), metabolic cluster (cluster 
4), psychological cluster (cluster 5) [39].  Assigning each patient to a specific cluster or 
determining the COTE index may be important for the overall management of patients. 
In the overall management of COPD patients, the assessment of comorbidities is a 
valuable tool to improve prognosis and quality of life because COPD and comorbidities 
synergize to define the health status. 
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5.0 Existing evidence for therapeutic management 
The therapeutic management of COPD should consider the patient as a whole and all 
interventions should be aimed to improve the overall health status. The worsening of COPD 
in patients with comorbidities may affect clinical outcomes and prognosis; therapies should 
be evaluated not only based on their safety and efficacy, but also on their ability to prevent 
exacerbations. However, it should be kept into account that COPD treatment may improve 
symptoms and decrease exacerbations, but does not prevent progression nor increase survival 
[40]. By contrast treatment of comorbidities may prolong survival and decrease health care 
utilization. Therefore, it is extremely important to promptly diagnose and treat comorbidities 
in these patients.  
Among non-pharmacological interventions, smoking cessation is a must to reduce the 
rate of lung function decline; vaccination against influenza is demonstrably linked to reduced 
exacerbations and mortality; pulmonary rehabilitation and interventions to increase physical 
activity are even recommended to improve the overall health status [5,33].  
Therapeutic options for COPD include β2-agonist and anticholinergics as 
bronchodilators, eventually associated with inhaled corticosteroids and phosphodiesterase-4 
inhibitors or macrolides for exacerbations. Among bronchodilators, β2-agonists (salmeterol, 
formoterol, indacaterol, salbutamol, olodaterol, vilanterol) and anticholinergics (ipratropium 
bromide, oxitropium bromide, aclidinium bromide, tiotropium bromide, glycopyrronium 
bromide, umeclidinium bromide) are associated with functional improvement of lung 
function, symptom control, and quality of life [41-45].  
Clinical guidelines and strategical plans for COPD management indicate that 
corticosteroids combined with long-acting β2-agonist are useful to reduce the effects of 
chronic inflammation, since they may contribute to improve lung function, delay disease 
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progression, and decrease symptoms and exacerbations [5,33]. However, the results of 
FLAME study indicate that the combination of long-acting β2-agonist (LABA) and long-
acting muscarinic receptor antagonist (LAMA) was superior to the combination of LABA 
and inhaled glucocorticoid in ameliorating exacerbations, lung function, and health status 
[46]. The effect was independent on blood eosinophil levels that did not correlate with the 
rate of moderate or severe exacerbations [47]. 
Phosphodiesterase-4 inhibitors are other anti-inflammatory agents, which inhibit the 
breakdown of intracellular cyclic AMP; they do not have direct bronchodilator activity, but 
improve FEV1 in patients treated with LABA and LAMA and reduce moderate and severe 
exacerbations with concomitant corticosteroids [5,48,49]. Long term treatment with 
macrolides may reduce exacerbations in severe COPD patients not controlled by inhalation 
therapy [50].  
Considering that COPD is a complex disease based on low grade systemic 
inflammation, it is also possible to target abnormal inflammation, either locally at pulmonary 
level or systemically. Some evidences indicate that pulmonary inflammation due to tobacco 
smoking not only leads to the structural changes observed in COPD, but also contributes to 
extrapulmonary systemic inflammation and comorbidities: smoking cessation and 
bronchodilators decrease dynamic hyperinflation and, therefore, reduce systemic 
inflammation [51]. Plasmatic CRP is increased in COPD patients and seems to contribute to 
atherosclerosis: based on this observation, inhaled corticosteroids (ICS) may potentially 
reduce the risk of cardiovascular diseases in COPD patients [12]. However, results on 
survival and risk of myocardial infarction are controversial and no evidence supports a 
negative relationship between ICS and mortality or cardiac adverse events in COPD patients, 
with or without concomitant cardiovascular disease [52]. 
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COPD patients present with a variable mix of distinct phenotypes such as 
emphysema, bronchitis, small airways disease, frequent vs infrequent exacerbators, or those 
with a rapid decline in lung function, which are independent of genetic background [53-54]. 
Including inflammatory markers in the definition of COPD sub-phenotype would enable to 
identify those patients who could benefit from more personalized approach in the future [41]. 
Targeting oxidative stress is another possible way to treat COPD. In COPD patients, 
glutathione (GSH) is increased to counter excess oxidant production; N-acetyl-l-cysteine acts 
as a precursor during GSH synthesis and it is currently used as a mucolytic and anti-
inflammatory agent in chronic bronchitis [56-58]. In recently published evidence-based 
guidelines on the prevention of acute exacerbations of COPD by American College of Chest 
Physicians and Canadian Thoracic Society, N-acetylcysteine therapy is recommended (grade 
2B) for patients with moderate to severe COPD and a history of two or more exacerbations in 
prior 2 years [59]. 
5.1 COPD and cardiovascular diseases 
The diagnostic challenge is to determine how COPD and comorbidities specifically 
contribute to the disease, when respiratory symptoms (dyspnea, cough, or wheezing) are 
overlapping, as in patients with decompensated heart failure, arrhythmias, and ischemic heart 
disease. On one hand, airway and lung inflammation contributes to a systemic inflammation 
which involves vessels, heart, and central nervous system and worsens concomitant 
cardiovascular or metabolic diseases; on the other, comorbidities (i.e. acute myocardial 
infarction, congestive heart failure, cerebrovascular disease, cardiac arrhythmias and 
pulmonary circulation disorders) produce acute events and affect morbidity and mortality 
during COPD exacerbations [60].  
Worldwide in general population, COPD prevalence ranges from 7 to 10%, and is 
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continuously increasing. In the US and Europe, COPD is the fourth cause of death. Ischemic 
heart disease with all its clinical manifestations, including silent ischemia, sudden death, 
angina, myocardial infarction, is the first cause of death in developed countries, and it will 
become soon the first in developing ones [61,62]. Therefore, it is presumable that COPD and 
ischemic heart disease frequently coexist in patients. In almost one third of patients, COPD is 
associated with cardiovascular diseases [63], which are ischemic heart diseases in a half of 
the patients [64]. The prevalence of ischemic heart disease in patients with COPD is double 
compared with that in general population [65]. COPD may induce ischemic heart disease or, 
at least, increase the risk for developing it, and it has been demonstrated that cardiovascular 
diseases and mortality correlate with pulmonary failure severity [66]. COPD and 
atherosclerosis, which foreshadows ischemic heart disease, share a similar pathogenesis, the 
smoking habit as major risk factor, and an increased level of many markers of systemic 
inflammation, including C reactive protein, IL-8, TNF-α, and fibrinogen. Three among these 
variables -age >40 years, smoking habit, COPD, heart failure, metabolic syndrome, high PCR 
levels- allow identifying patients with systemic chronic inflammation [67]. A case-control 
study with 11155 patients indicated that there was a strong relationship between pulmonary 
infection and incidence of first myocardial infarction within 1-4 weeks after the acute event 
[68]. Furthermore, anti-inflammatory agents, as phosphodiesterase 4 inhibitors, in addition to 
usual COPD therapy improved pulmonary function [69] and reduced exacerbations [70].  
Identifying concomitant COPD and heart failure may be challenging, with serious 
diagnostic and therapeutic consequences: a missed or delayed diagnosis of both conditions 
leads to under-evaluation and under-treatment of symptoms, wrongly attributed only to a 
disease, and complicates the therapeutic approach [71]. Patients with COPD had high 
prevalence of heart failure, as they are at highest risk for cardiovascular morbidity and 
mortality, regardless other risk factors. Almost 10-40% patients with heart failure are affected 
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by COPD, and among patients with COPD, the prevalence of heart failure and chronic 
pulmonary heart is almost 20% and 2%, respectively. Therefore, it is not surprising that the 
main cause of mortality in COPD patients is heart failure, and not respiratory failure [72], and 
it may be precautionary to manage patients with concomitant COPD and heart failure, as in 
presence of ventricular dysfunction until a different evaluation.  
Sometimes, COPD is the primary cause of cardiovascular diseases, i.e. in case of 
pulmonary heart. All morbidities which either directly or indirectly affect respiratory 
mechanical ventilation, gas exchanges, and pulmonary vascular bed, may determine 
pulmonary hypertension and chronic pulmonary heart. Pulmonary hypertension accounts for 
5-10% of all organic heart diseases and is reported in 20-30% of patients hospitalized for 
heart failure, who frequently are males, smokers, and 50-60 years old. There are many 
pathogenic mechanisms underlying pulmonary hypertension that, however, becomes evident 
when the vascular reserve is extremely limited and chronic. The primary pulmonary disease 
usually has a limited extension or do not affect gas exchanges and, therefore, do not trigger 
the process that leads to right ventricular hypertrophy and heart failure. 
Chronic cardiovascular comorbidity of COPD should be accurately investigated and 
evaluated for an appropriate diagnosis. Electrocardiogram, echocardiogram and biomarkers, 
such as N-terminal pro-brain natriuretic peptide (NT-probing) and troponin, may help to 
specify the diagnosis, but abnormalities of biomarkers or imaging are frequently observed 
also in COPD patients without over clinical manifestations of myocardial damage and/ or 
dysfunction [60]. The search of reliable biomarkers of respiratory symptom exacerbation is 
an unmet need that should be rapidly solved. Furthermore, an early identification of 
cardiovascular comorbidities in COPD patients and a prompt therapeutic treatment of 
singular disease may improve quality of life and prognosis of these patients [40].  These 
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observations are currently extrapolated from registries, observational studies or post-hoc 
analyses from clinical trials, but randomized clinical trials specifically designed to investigate 
the contribution of comorbidities in patients with COPD are lacking [40]. 
5.2 Management of cardiovascular disease concomitant with COPD 
Both acute and chronic lung inflammation contribute to cardiovascular morbidity in 
COPD patients [73,74]. Chronic lung and systemic inflammation results in increased plaque 
cell turnover and oxidative stress, thus leading to an accelerated plaque progression, 
development and rupture in the ischemic heart disease or carotid arterial disease (CAD) [73]; 
acute lung inflammation is mainly associated with acute coronary syndrome [74].  Clinicians 
managing patients with a significant smoking history or occupational or home exposure to 
dust and particles should evaluate both cardiovascular and respiratory systems for 
abnormalities. An algorithm to predict the risk of CAD in COPD patients has been proposed, 
using a non-invasive approach. The model was developed on 1596 patients undergoing 
coronary arteriography: gender (men/women OR: 1.7, 95%CI: 1.237–2.5, P < 0.05), 
dyslipidemia (OR: 1.8, 95%CI: 1.2–2.5, P < 0.01), and smoking habit (OR: 1.5, 95%CI: 1.2–
1.9, P < 0.001) were significantly associated with CAD in COPD and could specifically 
identify patients at risk with a high diagnostic accuracy [75].  
Cardiovascular safety should be monitored during COPD therapy for many reasons: 
both LAMAs and LABAs have a high potential to impact on cardiovascular activity [52]; 
COPD per se increases the cardiovascular risk; some patients may be on long-term treatment 
for previous cardiovascular diseases.  
Cardio- and cerebrovascular (CCV) safety is investigated during clinical 
developmental program, as a part of the comprehensive evaluation of safety [46]. A 
comparative analysis of safety data from phase III pivotal studies of at least 6 months 
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duration indicated that indacaterol, formoterol and salmeterol were not associated with a 
significant increase in relative risk of serious CCV events, compared to placebo. For its 
intended long-term regular use, CCV safety of indacaterol at highest doses (600µg) was 
evaluated: no apparent potential for increased risk was reported and most of CCV adverse 
events with indacaterol occurred in patients with pre-existing cardiovascular risk factors [76]. 
Similarly, cardiovascular safety was specifically assessed for LAMAs, which are known to 
be associated with cardiovascular adverse events, such as arrhythmias [77]. Tiotropium did 
not increase the risk of cardiac events, mortality and serious adverse events even in patients 
who experienced recent myocardial infarction, heart failure, and unstable rhythm disorders 
[78]. Glycopyrronium and tiotropium showed similar long-term safety in clinical trials and 
post-marketing surveillance period, without increasing CCV compared to placebo [79], as 
well as all approved LAMA/LABA fixed-dose combinations had similar cardiovascular 
safety as single agents. It should be considered that the high prevalence of comorbidities in 
COPD patients makes poorly reproducible the pictures of clinical trials, usually performed on 
highly selected populations [80]. A recent meta-analysis on 23,168 COPD patients confirmed 
that all LAMA/LABA combinations were always more effective than LAMA or LABA alone 
in improving trough FEV1, without increasing the cardiovascular risk [81]. 
COPD per se increases the risk of cardiovascular diseases, such as angina, 
arrhythmias, congestive heart failure, and myocardium infarction [66], and heart failure is a 
strong independent predictor of all-cause mortality in COPD patients [82]. The presence of 
COPD affects the choice of pharmacological treatment for concomitant heart failure: per 
instance, β-blockers are less frequently used in COPD patients, than in general population 
[83]. However, based on retrospective studies, the pooled relative risk of COPD-related 
mortality secondary to β-blocker use was 0.69 (95% CI: 0.62-0.78; I2=82%) [84] and some 
authors reported that β-blockers may reduce exacerbations in patients with both mild and 
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severe disease [85,86]. β-blockers more selective for the β (1)-AR are more appropriate for 
COPD patients, with an attentive monitoring of lung function and symptoms [87]. 
Prospective real-world clinical studies on β-blockers in COPD patients should be 
recommended. 
In addition to traditional therapies targeted on lungs, newer strategies potentially able 
to affect and mitigate cardiovascular risks in patients with COPD should be considered: 
angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, and β-
adrenoceptor blockers, in addition to their benefit on treating comorbidities, might affect 
COPD [75], and early data suggest that may improve survival and reduce hospitalization, due 
to acute exacerbations of COPD [51].  
6.0 COPD, depression, and cognitive dysfunction 
Over 40% of elderly patients with COPD show clinically significant depressive 
symptoms that may warrant medical intervention and interfere in their daily activities and 
self-management of respiratory condition [88]. Long-term studies suggest that there is a 
bidirectional relationship between COPD and depression: COPD persistently increases the 
risk of depression and, the presence of depression contributes to worsen COPD course and 
affect the response during exacerbations [89]. From a molecular point of view, developing 
depressive symptoms and excessive fatigue that interfere in daily activities were associated 
with systemic inflammation and increased levels of tumor necrosis factor alpha (TNFα) [89]. 
However, the exact mechanism or pathway by which COPD patients develop depression is 
still uncertain. It is most likely the complex interaction of physical, behavioral, physiological 
and systemic inflammation that may contribute to an increased risk of depressive symptoms. 
Short-term intervention studies suggest that both pulmonary rehabilitation and cognitive 
behavioral therapies are beneficial in improving depressive symptoms and quality of life, but 
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 2
3:5
9 1
6 D
ec
em
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
 
the long-term efficacy of these approaches is unknown [90-92].  
Cognitive functions should be evaluated before developing a self-management plan to 
comply with patient’s needs and skills, since these factors can directly affect the adherence to 
treatment [93]. Tulek et al. [93] showed a negative association between cognitive function 
and number of exacerbations: COPD exacerbations increased C reactive protein (CRP) 
levels, fibrinogen, and leukocytes and this systemic inflammation impaired the cognitive 
abilities required to perform the MMSE (Mini Mental State Examination) and the Brown-
Peterson tests [93]. The MMSE test is commonly used in almost all clinical domains and it 
may be useful also for COPD patients [93]. Once evaluated the cognitive function, 
medications and therapies should be systematically reviewed to optimize the adherence and 
avoid adverse effects.  
The high incidence of comorbidities in COPD patients implies the combination of 
multiple drugs, with an increased risk of adverse events. Molecules and schedules should be 
attentively chosen and monitored to immediately identify a drug-related symptom [94]. The 
risk associated to polytherapy is particularly high for elderly subjects, as COPD patients 
commonly are. Therefore, it is important to determine how healthy the elderly subject is 
through validated and suitable parameters, and to identify those patients who could benefit 
from a combined approach for COPD and comorbidities. 
6.1 Elderly, COPD and frailty 
Elderly patients with COPD are often defined as frail subjects [95,96]. Frailty is a 
progressive physiological decline in multiple organ systems marked by loss of function, loss 
of physiological reserve and increased vulnerability to disease [97]. Biological (inflammation 
and loss of hormones), clinical (e.g. sarcopenia and osteoporosis) and social factors are 
involved in frailty onset, evolution and prognosis [98,99] and should be considered in COPD 
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patient management. Frailty and respiratory impairment are strongly related and substantially 
increase the risk of death, when both are present [100].  
Gait speed is a key marker of frailty: in the COPD context, it may capture many 
systemic effects of disease severity, rather than pulmonary function assessment alone, and it 
may reflect the global-wellbeing of subject. The gait speed is commonly assessed by exercise 
capacity in the 6-minute walk distance test in both clinical trial, as an outcome of lung 
function, and daily practice, as an indicator of lung functional capacity [101]. The gait speed 
decreases with COPD severity and is associated with age, clinical symptoms, pulmonary 
functions, and quality of life scores [100]. Standardizing the gait speed test may be important 
to obtain normative gait speed data, define their relationship with morbidity and mortality 
rates, and compare the effects of different treatment modalities, such as supplemental oxygen 
and corticosteroids [102].  
Another useful test to assess the performance status in COPD patients is the Short 
Physical Performance Battery (SPPB). The SPPB includes results from three component tests 
of functional relevance: standing balance, 4-meter gait speed (4MGS), and five-repetition sit-
to-stand motion (5STS). Each component is scored based on a subscale and the three sub-
scores are summed to obtain the final score. The SPPB has been validated for assessing 
mobility limitations in COPD patients and its results have significantly associated with the 
ability to perform physical activities in daily living, such as changing and maintaining body 
position, carrying, moving and handling objects, or walking [103]. Patients with COPD 
should be screened with SPPB to early identify subjects with limited mobility who may 
require supplemental rehabilitation strategies to prevent disability and restore normal 
function [103].  
Therefore, SPPB, 6-minute walk distance test and lung function assessment, all 
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together, are useful parameters to build a complete picture of a patient and propose an 
appropriate therapeutic intervention, because identifying the link between frailty, dyspnea, 
and chronic respiratory diseases represents a novel and practical approach to manage COPD 
patients. An increase in functional capacity, measured by gait speed or SPPB, may be an 
interesting target for therapy in frail elderly COPD subjects. 
6.2 COPD and osteoporosis 
The prevalence of osteoporosis in COPD patients varies between 9–69%, depending 
on diagnostic methods, population, and severity of underlying respiratory disease, and is 
assumed to be two- to fivefold higher than counterparts without airflow obstruction [104]. 
COPD and osteoporosis share common risk factors, including past or current tobacco 
smoking, inactivity, and cachexia that are mainly associated with a decreased bone mineral 
density [105]; COPD itself is an independent predictor of bone mineral density reduction and 
increased risk of vertebral fractures [106]. COPD patients should be encouraged to avoid 
bone loss, recommending physical exercises, when feasible, rehabilitation programs, and 
counselling on fall prevention [107]. In the COPD management, corticosteroids should be 
limited and replaced with other therapies which favor bronchodilation and prevent 
exacerbation. During oral glucocorticosteroids treatment, a concomitant antiresorptive 
therapy should be considered, because bone loss starts immediately, in a daily dose 
relationship [107]. 
6.3 COPD and A1AT deficiency 
Systemic deficiency of alpha-1 antitrypsin (A1AT) leads to an increase susceptibility 
to chronic inflammatory conditions, including COPD. A1AT deficiency underlies 
approximately 5% of all cases of COPD [108]. In these patients, the augmentation therapy 
with plasma-derived A1AT reduces the rate of lung function decline and the frequency of 
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exacerbations, and shows significant benefit in subjects having FEV1 in the range of 35-49% 
of predicted normal [109].  
6.4 Cachexia and malnutrition in COPD 
Cachexia is a complex syndrome frequently present in COPD patients and is 
associated with increased mortality, poor health-related quality of life, and muscle weakness 
[110]. The clinical phenotype of cachexia ranges from minimal or no weight loss, with signs 
of muscle wasting (e.g. anorexia, inflammation) to severe weight loss, muscle depletion, 
fatigue, and reduced mobility [111]. In patients with COPD and either overt cachexia or 
minimal weight loss, early nutritional support has shown clinical benefits on body weight, 
fat-free mass index, exercise tolerance, and respiratory and non-respiratory muscle strength, 
without safety issues [111].  
7.0 Conclusion 
A number of COPD patients have concomitant morbidities. Some of them may be 
independent of COPD and result from aging process, some may be direct consequences of 
COPD, and some may be caused by the same risk factors, mainly smoking.  Irrespective of 
the links between COPD and comorbidities, physicians must be aware of their existence to 
make a suitable therapeutic plan for each individual patient. Pulmonary function testing 
remains the cornerstone for diagnosis, but it should not be always limited to simple 
spirometry. Bronchodilation is the first-line treatment for the majority of COPD patients even 
in the presence of comorbidities, which must be treated appropriately, keeping in mind 
possible drug interactions.  
8.0 Expert commentary 
The presence of multiple comorbidities in COPD patients complicates the clinical 
management of the disease. The goals in this field are to personalize all the therapeutic plan, 
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from diagnosis to treatment, and to consider the peculiar characteristics of each patient. 
Firstly, an accurate assessment of respiratory function should be performed, and combining 
clinical and functional data will allow distinguishing patients with prevalent emphysema 
from those with prevalent chronic bronchitis. In addition to lung function assessment, other 
tests, including the Short Physical Performance Battery, the 6-minute walk distance test, the 
Mini Mental State Examination may be useful to obtain a complete picture of patient 
functioning and to propose the most appropriate therapeutic intervention. Similarly, 
depressive symptoms or malnutrition and cachexia should be recognized at early stage and 
promptly managed. Therefore, identifying the link between frailty, comorbidities, and 
chronic respiratory diseases will represent the most effective practical approach to diagnose 
and manage COPD patients, especially elderly ones. In presence of comorbidities, their 
treatment may prolong survival and impact on health care costs, unlike COPD treatments that 
may improve symptoms and decrease exacerbations, but does not prevent progression nor 
increase survival. Thus, the therapeutic plan of COPD should consider the patient as a whole 
and all interventions should be aimed to improve the overall health status and to treat or, at 
least, do not worsen comorbidities. Careful attention should be focused on patients with co-
existing cardiovascular conditions and cardiovascular safety should be monitored during 
COPD therapy since bronchodilators -both LAMAs and LABAs- have a high potential to 
impact on cardiovascular activity, COPD per se increases the cardiovascular risk, and long-
term treatment for previous cardiovascular diseases may be ongoing. Furthermore, the high 
incidence of comorbidities in COPD patients implies the combination of multiple drugs, with 
an increased risk of adverse events. Molecules and schedules should be attentively chosen 
and monitored to avoid drug- drug interactions and to immediately identify drug-related 
symptoms. 
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Therefore, a future challenge will be to identify for each patient a personalized and 
multidimensional approach that will consider the patient as a whole. In the management of 
patients with COPD the goal that need to be achieved is the strong collaboration of key areas 
that include pulmonary medicine, geriatrics and cardiology. 
Complete pulmonary profile, based on age, gender and the presence of comorbidity 
along with additional functional parameters to be validated are necessary for a proper 
assessment of the complexity of this kind of patient. 
At present, the areas of interest of research are focused on COPD diagnosis and 
pharmacodynamic interactions between treatments, to both manage COPD and address 
specific comorbidities, and further deepen the role of inflammation in COPD pathogenesis. 
Establishing the correct relationship between COPD and inflammation and aging would 
contribute to further improve clinical outcomes of patients and develop strategies to prevent 
the disease.  Cardiovascular safety will be another point of clinical importance in COPD 
patient management and research in this field.  
In the coming years, the majority of patients with COPD will be elderly, hill, and 
frail. It will be important to adapt current strategies to this population or identify novel 
approaches through validated and suitable parameters. 
 
9.0 Five-year view 
 In 5 years, the COPD landscape will change; further improvement will be done to 
assess a complete pulmonary profile and to address comorbidities. Therapies will be 
personalized, taking advantage of a wide availability of drugs, with well differentiated 
pharmacological characteristics.  
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Key issues 
• COPD is characterized by a slowly progressive deterioration in lung function, mostly 
becoming evident with aging. COPD is frequently associated with other age-related 
morbid conditions, which may exist independently, or as consequences of COPD, or 
because they share common risk factors.   
• Pulmonary function testing remains the cornerstone for diagnosis, but it should not be 
always limited to simple spirometry. Indeed, spirometric measurements are good 
survival predictors, but loosely correlated with patient-centered outcomes, such as 
dyspnea, quality of life, exercise tolerance. 
• In the overall management of COPD patients, the assessment of comorbidities is a 
valuable tool to improve prognosis and quality of life: the patient is currently 
considered as a whole, in whom COPD and other comorbidities synergize to define 
the health status.   
• Both acute and chronic lung inflammation contributes to cardiovascular morbidity in 
COPD patients. 
• Cardiovascular safety should be monitored during COPD therapy for many reasons: 
both LAMAs and LABAs have a high potential to impact on cardiovascular activity; 
COPD per se increases the cardiovascular risk; some patients may be on long-term 
treatment for previous cardiovascular diseases. 
• In the treatment of patients with COPD, clinicians must look beyond the lung and 
develop therapeutic approaches to prevent or mitigate cardiovascular risks associated 
with COPD. 
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